Development of Novel Nano Hyaluronic Acid Carrier for Diagnosis and Therapy of Atherosclerosis

For an efficient atherosclerosis diagnosis and treatment, we have a persistent requirement of developing a carrier that can precisely carry agents into the pathological location. Herein we examined the ability of hyaluronic acid nanoparticles (HA NPs) as a carrier for the active aiming of atherosclerosis. To prepare HA NPs, 100 mg of Hyaluronic acid was added to 20 ml of formamide, and 61 mg of EDC followed by adding 36.4 mg of NHS in order to activate -COOH functionalities of HA. The resultant mixture was then added with 33.16 mg of aminated 5b-cholanic acid in 40 ml of DMF under contentious stirring at standard temperature conditions for about 12 h, followed by purification and lyophilization. The prepared NPs were examined to study their use in the treatment of atherosclerosis. The prepared HA NPs were studied by using different characterization techniques. By in vitro cellular acceptance investigation, it was exposed that the HA NPs were taken up selectively by over expressing the cells CD44 or stabilin-2. Conversely, the cellular acceptance of HA NPs was noticed to be decreased extremely by pretreating the cells with surplus quantity of free HA, indicating that the HA NPs was taken up by the receptor intervened endocytosis. In conclusion, HA NPs were prepared and confirmed by using different characterization techniques. Also, the prepared HA NPs possesses high ability to be a carrier for the atherosclerosis diagnosis and treatment.